Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Biotinidase is an enzyme (EC 3.5.1.12) encoded by the BTD gene located on chromosome 3p25, responsible for cleaving biotin (vitamin H) from biocytin (biotinyl-lysine) and from biotin-bound peptides, thus recycling biotin for reuse as a cofactor by carboxylase enzymes involved in the metabolism of fats, carbohydrates, and proteins[1][5]. Its deficiency, inherited in an autosomal recessive manner, results in impaired biotin recycling, leading to multiple carboxylase deficiency with neurocutaneous and metabolic manifestations, but can be effectively treated and prevented by oral biotin supplementation[2][5]. The enzyme is a glycoprotein with multiple isoforms and glycosylation sites, exhibits a catalytic triad (glutamate, lysine, cysteine), and acts primarily in tissues with high metabolic demand including liver and brain[3][5]. Biotinidase deficiency is included in newborn screening programs due to the severity but treatability of disease upon early detection[5][7].
Biotin supplementation compensates for endogenous enzyme deficiency by providing free biotin that bypasses the need for biotin release by biotinidase
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Biotinidase (BTD).